Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection.
COVID-19
ICU – intensive care unit
acute respiratory distress syndrome
bronchial aspirate
proteomics
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
05
2022
accepted:
04
07
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
17
8
2022
Statut:
epublish
Résumé
Bronchial aspirates (BAS) obtained during invasive mechanical ventilation (IMV) constitutes a useful tool for molecular phenotyping and decision making. To identify the proteomic determinants associated with disease pathogenesis, all-cause mortality and respiratory sequelae in BAS samples from critically ill patients with SARS-CoV-2-induced ARDS. Multicenter study including 74 critically ill patients with COVID-19 and non-COVID-19 ARDS. BAS were obtained by bronchoaspiration after IMV initiation. Three hundred sixty-four proteins were quantified using proximity extension assay (PEA) technology. Random forest models were used to assess predictor importance. After adjusting for confounding factors, CST5, NADK, SRPK2 and TGF-α were differentially detected in COVID-19 and non-COVID-19 patients. In random forest models for COVID-19, CST5, DPP7, NADK, KYAT1 and TYMP showed the highest variable importance. In COVID-19 patients, reduced levels of ENTPD2 and PTN were observed in nonsurvivors of ICU stay, even after adjustment. AGR2, NQO2, IL-1α, OSM and TRAIL showed the strongest associations with in-ICU mortality and were used to construct a protein-based prediction model. Kaplan-Meier curves revealed a clear separation in mortality risk between subgroups of PTN, ENTPD2 and the prediction model. Cox regression models supported these findings. In survivors, the levels of FCRL1, NTF4 and THOP1 in BAS samples obtained during the ICU stay correlated with lung function (i.e., D BAS proteomics identified novel factors associated with the pathology of SARS-CoV-2-induced ARDS and its adverse outcomes. BAS-based protein testing emerges as a novel tool for risk assessment in the ICU.
Identifiants
pubmed: 35967328
doi: 10.3389/fimmu.2022.942443
pmc: PMC9373836
doi:
Substances chimiques
AGR2 protein, human
0
Mucoproteins
0
Oncogene Proteins
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
SRPK2 protein, human
EC 2.7.11.1
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
942443Informations de copyright
Copyright © 2022 Molinero, Gómez, Benítez, Vengoechea, González, Polanco, Gort-Paniello, Moncusí-Moix, García-Hidalgo, Perez-Pons, Belmonte, Torres, Caballero, Barberà, Ayestarán Rota, Socías Crespí, Ceccato, Fernández-Barat, Ferrer, Garcia-Gasulla, Lorente-Balanza, Menéndez, Motos, Peñuelas, Riera, Torres, Barbé and de Gonzalo-Calvo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Signal Transduct Target Ther. 2020 Oct 7;5(1):227
pubmed: 33028824
Arch Bronconeumol. 2022 Feb;58(2):142-149
pubmed: 34497426
Crit Care Med. 2022 Feb 1;50(2):245-255
pubmed: 34259667
Clin Transl Med. 2022 May;12(5):e838
pubmed: 35538880
FEBS J. 2021 Sep;288(17):5190-5200
pubmed: 33098359
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Front Med (Lausanne). 2021 Mar 22;8:653773
pubmed: 33829029
Cell. 2022 Mar 3;185(5):881-895.e20
pubmed: 35216672
Crit Care Med. 2020 Sep;48(9):e799-e804
pubmed: 32452888
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
Cells. 2021 Mar 10;10(3):
pubmed: 33801959
Can J Infect Dis Med Microbiol. 2022 May 28;2022:7336309
pubmed: 35669528
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
J Thorac Oncol. 2011 Oct;6(10):1632-8
pubmed: 21694641
Am J Respir Crit Care Med. 2022 Jun 7;:
pubmed: 35671465
EBioMedicine. 2022 Mar;77:103894
pubmed: 35217407
J Clin Neurosci. 2022 Jul;101:264-275
pubmed: 35660960
Front Immunol. 2021 Nov 18;12:742822
pubmed: 34867965
Acta Biomed. 2022 Jun 07;93(S1):e2022102
pubmed: 35671104
J Gen Virol. 2007 Aug;88(Pt 8):2101-2105
pubmed: 17622610
Nucleic Acids Res. 2021 Jan 8;49(D1):D1144-D1151
pubmed: 33237278
Transl Res. 2022 Apr;242:1-19
pubmed: 34954088
Front Med (Lausanne). 2022 Feb 03;8:756517
pubmed: 35186962
EBioMedicine. 2017 Mar;17:172-181
pubmed: 28238698
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
Sci Signal. 2021 Jul 06;14(690):
pubmed: 34230210
J Allergy Clin Immunol. 2021 Jan;147(1):81-91
pubmed: 32979342
Pulm Circ. 2020 Nov 25;10(4):2045894020966547
pubmed: 33282193
Clin Microbiol Infect. 2020 Dec;26(12):1706-1708
pubmed: 32659385
Cancer Res. 2004 Aug 1;64(15):5178-85
pubmed: 15289322
JCI Insight. 2020 Jul 23;5(14):
pubmed: 32559180
J Neurosci. 1998 May 15;18(10):3699-707
pubmed: 9570800
Arch Biochem Biophys. 2002 Jan 15;397(2):162-71
pubmed: 11795867
Crit Care. 2021 Jan 9;25(1):23
pubmed: 33422148
Biomolecules. 2020 Feb 17;10(2):
pubmed: 32079362
Nat Immunol. 2011 Jan;12(1):45-53
pubmed: 21151101
Adv Clin Chem. 2020;98:51-89
pubmed: 32564788
Eur Respir J. 2022 Feb 10;59(2):
pubmed: 34824059
J Biol Chem. 2009 Oct 9;284(41):28021-28032
pubmed: 19661059
Crit Care Clin. 2022 Jul;38(3):505-519
pubmed: 35667740
Chest. 2021 Jul;160(1):187-198
pubmed: 33676998
Oral Microbiol Immunol. 1998 Feb;13(1):59-61
pubmed: 9573825
Sci Adv. 2019 Jul 17;5(7):eaaw0315
pubmed: 31328160
Thorax. 2019 Oct;74(10):947-957
pubmed: 31076499
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194
J Proteome Res. 2021 Oct 1;20(10):4627-4639
pubmed: 34550702